Ardeparin
Pharmaceutical drug
- None
- US: ℞-only
- 6-[5-acetylamino-4,6-dihydroxy-2-(sulfooxymethyl)tetrahydropyran-3-yl]oxy-3-[5-(6-
- 9041-08-1
Y
- DB00407
N
- none
- N3927D01PB
- ChEMBL1201448 N
- DTXSID301010914
N
Y (what is this?) (verify)Ardeparin (brand name Normiflo) is an anticoagulant. It was used for the prevention of deep vein thrombosis, but was withdrawn from the US market in 2000 for reasons unrelated to safety or efficacy.[1][2][3]
References
- ^ Frishman WH, Cheng-Lai A, Chen J (2000). "Antithrombotic therapy". Current cardiovascular drugs (3rd ed.). Philadelphia, Pa.: Current Medicine. p. 90. ISBN 978-1-4615-6767-7.
- ^ "Normiflo". Drugs.com. Archived from the original on 19 February 2017. Retrieved 23 January 2018.
- ^ "Determination That Ardeparin Sodium Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness". United States Food and Drug Administration. Federal Register. Retrieved 24 June 2022.
- v
- t
- e
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
| Glycoprotein IIb/IIIa inhibitors |
|
|---|---|
| ADP receptor/P2Y12 inhibitors | |
| Prostaglandin analogue (PGI2) | |
| COX inhibitors | |
| Thromboxane inhibitors | |
| Phosphodiesterase inhibitors | |
| Other |
| Vitamin K antagonists (inhibit II, VII, IX, X) | |||||
|---|---|---|---|---|---|
| Factor Xa inhibitors (with some II inhibition) |
| ||||
| Direct thrombin (IIa) inhibitors |
| ||||
| Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Portal:
Medicine
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
